Study of combination of vildagliptin with metformin and glimepiride with metformin in type2 diabetic patients
Phase 4
Completed
- Conditions
- Health Condition 1: E119- Type 2 diabetes mellitus without complications
- Registration Number
- CTRI/2022/01/039090
- Lead Sponsor
- avreet Kaur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 80
Inclusion Criteria
Patients above 18 years old age, of either sex with type 2 diabetes mellitus
Newly diagnosed type 2 diabetes mellitus patient with HBA1C >8%
Exclusion Criteria
Other types of diabetes
patients with inflammatory disease (inflammatory bowel disease, lupus, arthritis), hepatic or renal impairment, malignancy, thrombosis and conditions other than type 2 diabetes mellitus
Who are on steroids, anti-inflammatory and immunomodulatory drugs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method to assess the effect of combination therapy on the glycemic level and inflammatory markersTimepoint: FBS/RBS at 0,2,4,8,10,12 weeks while HBA1C and inflammatory markers(IL6, hCRP and ESR) at 0 and 12 weeks, <br/ ><br>Other test LFT and RFT 0,2,4,8,10,12 weeks <br/ ><br>
- Secondary Outcome Measures
Name Time Method Assess the adverse eventsTimepoint: during and after study period